AdvisorShares Investments LLC Acquires 5,560 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AdvisorShares Investments LLC increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 113.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,460 shares of the specialty pharmaceutical company’s stock after buying an additional 5,560 shares during the quarter. AdvisorShares Investments LLC’s holdings in Jazz Pharmaceuticals were worth $1,288,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Northern Trust Corp boosted its position in Jazz Pharmaceuticals by 18.9% in the fourth quarter. Northern Trust Corp now owns 521,196 shares of the specialty pharmaceutical company’s stock valued at $64,185,000 after buying an additional 82,817 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Jazz Pharmaceuticals by 1.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 353,467 shares of the specialty pharmaceutical company’s stock valued at $43,529,000 after purchasing an additional 5,715 shares during the last quarter. Quarry LP raised its position in Jazz Pharmaceuticals by 6.3% in the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $209,000 after purchasing an additional 100 shares during the last quarter. Tri Locum Partners LP acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $19,927,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $10,245,000. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on JAZZ shares. JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, April 10th. Royal Bank of Canada decreased their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Finally, HC Wainwright increased their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Stock Up 1.9 %

Shares of NASDAQ:JAZZ opened at $112.89 on Tuesday. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a market capitalization of $6.86 billion, a PE ratio of 15.90, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The business has a fifty day moving average price of $124.20 and a two-hundred day moving average price of $122.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the transaction, the chief executive officer now directly owns 440,307 shares in the company, valued at $54,487,991.25. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,736 shares of company stock worth $4,023,305. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.